Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX 04:00:11 2024-04-22 pm EDT 5-day change 1st Jan Change
128.2 USD +1.96% Intraday chart for Merck & Co., Inc. +0.54% +16.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer MT
BMO Capital Adjusts Price Target on Merck & Company to $148 From $132 MT
Leerink Partners Raises Merck's Price Target to $134 From $129 MT
Zacks Adjusts Price Target on Merck & Company to $132 From $128 MT
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust CI
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center CI
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner CI
Transcript : Merck & Co., Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024 09:55 AM
S&P 500 ends slightly higher as markets brace for inflation data, earnings RE
Wall St backs down as markets brace for inflation data, earnings RE
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study MT
Moderna jumps as personalized cancer vaccine shows benefit in early study RE
Berenberg Raises Price Target on Merck & Company to $143 From $140, Maintains Buy Rating MT
Geneos cancer vaccine shrinks liver tumors in small trial RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
Merck & Co., Inc. acquired Abceutics, Inc. for approximately $210 million. CI
Merck Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy MT
Merck: launches phase III trial in lung cancer CF
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer CI
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer MT
Merck: 1st patient in raludotatug study CF
US takes next step in Medicare drug price negotiations with pharma companies RE
Robert Davis, Merck CEO: Another obesity drug? MT
Merck: new indication approved for Keytruda in Europe CF
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
125.8 USD
Average target price
137.6 USD
Spread / Average Target
+9.38%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Sector Update: Health Care Stocks Edge Higher Premarket Thursday